A Russian study to determine the severity and lethality of COVID-19 infection in patients with hematologic diseases
Description of the Study:
- Title: Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19).
- Principal Investigators: Olga A. Gavrilina, Kristina Zakurdaeva, Vladimir I. Vorobyev, Anastasia N. Vasileva, Lev S. Butaev, Alena Sukhareva, Lubov Gavrilova, Olga Samoylova, Maria Grishunina, Ochsana Ochirova, Alina Karpova, Olga Panteleeva, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika Rakhmani, Tatiana V. Gaponova, Gennadiy M. Galstyan, Vera V. Troitskaya, Anton V. Luchkin, Elena N. Parovichnikova and Valery Savchenko.
- Center of Implementation: National Research Center for Hematology, Foundation for Cancer Research Support, Regional Clinical Hospital No1 (Ekaterinburg, Russian Federation), Republican Clinical Hospital of Tatarstan (Kazan, Russian Federation), City Hospital n.a. V.V. Veresaev (Moscow, Russian Federation), Clinical Hospital n.a. S.P. Botkin (Moscow, Russian Federation), Et al.
- Study Population: Patients with blood disease (both malignant and non-malignant) infected with SARS-CoV-2 infection, aged 18 or older.
- Study Type: Observational Prospective Cohort Study.
- Design: The primary measured outcome is 30-day all-cause mortality. And the secondary measured outcomes are:
– Rate of COVID-19 complications (30 day)
– Rate of ICU admission (30 day)
– Rate of mechanical ventilation / O2 requirement (30 day)
– Rate of relapse or progression of hematologic disease (30, 90 and 180 day)
– Overall survival (30, 90 and 180 day)
– Putative risk factors for the severity and lethality of COVID-19 (30, 90 and 180 day)
Objectives of the Study:
Principal Objective: The objective of the study is determine the treatment outcomes in patients with hematologic diseases and COVID-19.
(1) Describe the clinical course of COVID-19 in patients with hematologic disease.
(2) Determine the course and outcomes of hematologic disease in SARS-CoV-2 infected patients.
(3) Explore putative risk factors for the severity and lethality of COVID-19.
More about this Study:
CHRONOS19 is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in the online data collection form in a de-identified manner. This form includes questions about general clinical history of hematologic disease, manifestation, treatment, and the course of COVID-19, concomitant conditions, consequences on the hematologic disease, short-term and long-term outcomes. It will take approximately 10 min to answer the questions. Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for hematologic disease outcomes and overall survival assessment.
Other Epidemiological Studies:
This study aims to assess the mental health impact and needs associated with COVID-19 in Spain.
CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.
This study aims to identify socio-demographic factors, places frequented and behaviours associated with an increased risk of SARS-CoV-2 infection.
This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.
Cross-sectional study that analyzes whether the COVID-19 pandemic has strongly impacted the practice of dentistry in Colombia, generating changes in clinical activities and career prospects.
Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients
Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.
This retrospective observational study aims to clinically characterise patients with COVID-19 in Primary Care in Catalonia.
This study aims to develop alternative diagnostic tools that reliably assess COVID-19 infection, and that are low cost and easy to administer to the entire population.